S&P 500   3,960.27 (+0.67%)
DOW   33,719.47 (+0.36%)
QQQ   283.40 (+1.02%)
AAPL   141.98 (+0.74%)
MSFT   246.69 (+0.95%)
META   115.51 (+1.39%)
GOOGL   94.03 (-0.96%)
AMZN   89.79 (+1.50%)
TSLA   172.39 (-0.95%)
NVDA   169.16 (+4.94%)
NIO   13.32 (+5.88%)
BABA   94.02 (+6.44%)
AMD   69.77 (-0.53%)
T   19.12 (-0.93%)
MU   55.14 (+2.45%)
CGC   2.99 (-7.72%)
F   13.11 (+0.08%)
GE   83.24 (-2.07%)
DIS   92.34 (+0.21%)
AMC   6.14 (+1.49%)
PYPL   74.22 (-0.27%)
PFE   51.68 (+2.87%)
NFLX   308.23 (-0.06%)
S&P 500   3,960.27 (+0.67%)
DOW   33,719.47 (+0.36%)
QQQ   283.40 (+1.02%)
AAPL   141.98 (+0.74%)
MSFT   246.69 (+0.95%)
META   115.51 (+1.39%)
GOOGL   94.03 (-0.96%)
AMZN   89.79 (+1.50%)
TSLA   172.39 (-0.95%)
NVDA   169.16 (+4.94%)
NIO   13.32 (+5.88%)
BABA   94.02 (+6.44%)
AMD   69.77 (-0.53%)
T   19.12 (-0.93%)
MU   55.14 (+2.45%)
CGC   2.99 (-7.72%)
F   13.11 (+0.08%)
GE   83.24 (-2.07%)
DIS   92.34 (+0.21%)
AMC   6.14 (+1.49%)
PYPL   74.22 (-0.27%)
PFE   51.68 (+2.87%)
NFLX   308.23 (-0.06%)
S&P 500   3,960.27 (+0.67%)
DOW   33,719.47 (+0.36%)
QQQ   283.40 (+1.02%)
AAPL   141.98 (+0.74%)
MSFT   246.69 (+0.95%)
META   115.51 (+1.39%)
GOOGL   94.03 (-0.96%)
AMZN   89.79 (+1.50%)
TSLA   172.39 (-0.95%)
NVDA   169.16 (+4.94%)
NIO   13.32 (+5.88%)
BABA   94.02 (+6.44%)
AMD   69.77 (-0.53%)
T   19.12 (-0.93%)
MU   55.14 (+2.45%)
CGC   2.99 (-7.72%)
F   13.11 (+0.08%)
GE   83.24 (-2.07%)
DIS   92.34 (+0.21%)
AMC   6.14 (+1.49%)
PYPL   74.22 (-0.27%)
PFE   51.68 (+2.87%)
NFLX   308.23 (-0.06%)
S&P 500   3,960.27 (+0.67%)
DOW   33,719.47 (+0.36%)
QQQ   283.40 (+1.02%)
AAPL   141.98 (+0.74%)
MSFT   246.69 (+0.95%)
META   115.51 (+1.39%)
GOOGL   94.03 (-0.96%)
AMZN   89.79 (+1.50%)
TSLA   172.39 (-0.95%)
NVDA   169.16 (+4.94%)
NIO   13.32 (+5.88%)
BABA   94.02 (+6.44%)
AMD   69.77 (-0.53%)
T   19.12 (-0.93%)
MU   55.14 (+2.45%)
CGC   2.99 (-7.72%)
F   13.11 (+0.08%)
GE   83.24 (-2.07%)
DIS   92.34 (+0.21%)
AMC   6.14 (+1.49%)
PYPL   74.22 (-0.27%)
PFE   51.68 (+2.87%)
NFLX   308.23 (-0.06%)
NASDAQ:OMIC

Singular Genomics Systems - OMIC Stock Forecast, Price & News

$1.94
+0.12 (+6.59%)
(As of 12/8/2022 02:37 PM ET)
Add
Compare
Today's Range
$1.85
$1.96
50-Day Range
$1.82
$2.66
52-Week Range
$1.80
$12.43
Volume
1,146 shs
Average Volume
122,990 shs
Market Capitalization
$138.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.50

Singular Genomics Systems MarketRank™ Forecast

Analyst Rating
Hold
1.67 Rating Score
Upside/​Downside
80.4% Upside
$3.50 Price Target
Short Interest
Bearish
7.68% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.37) to ($1.49) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.53 out of 5 stars

Medical Sector

932nd out of 1,022 stocks

Analytical Instruments Industry

26th out of 28 stocks

OMIC stock logo

About Singular Genomics Systems (NASDAQ:OMIC) Stock

Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. The company manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits. It also offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics, and proteomics in one integrated instrument providing a versatile multiomics solution. The company has partnerships with Agilent Technologies, Dovetail Genomics, Lexogen, New England Biolab, QIAGEN, Roche, Twist Bioscience, and Watchmaker Genomics to validate their library preparation kits on the G4, as well as the Broad Institute of MIT and Harvard to connect the G4 to Terra platform, a data platform. Singular Genomics Systems, Inc. was incorporated in 2016 and is headquartered in La Jolla, California.

Receive OMIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Singular Genomics Systems and its competitors with MarketBeat's FREE daily newsletter.

OMIC Stock News Headlines

Singular Genomics Systems, Inc. (OMIC)
Apple To $220? Here Are 5 Other Price Target Changes For Wednesday
4 Analysts Have This to Say About Singular Genomics Sys
See More Headlines
Receive OMIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Singular Genomics Systems and its competitors with MarketBeat's FREE daily newsletter.

OMIC Company Calendar

Last Earnings
11/09/2021
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/01/2023

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OMIC
Fax
N/A
Employees
221
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.50
High Stock Price Forecast
$4.50
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+80.4%
Consensus Rating
Hold
Rating Score (0-4)
1.67
Research Coverage
3 Analysts

Profitability

Net Income
$-98,770,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.67 per share

Miscellaneous

Free Float
55,261,000
Market Cap
$138.52 million
Optionable
Not Optionable
Beta
0.99

Key Executives

  • Mr. Andrew Spaventa (Age 37)
    Founder, CEO, Pres & Chairperson of the Board
    Comp: $677.71k
  • Dr. David L. Barker Ph.D. (Age 80)
    Founder, Member of Scientific Advisory Board & Independent Director
    Comp: $32.82k
  • Ms. Daralyn Durie (Age 54)
    Gen. Counsel
    Comp: $449.73k
  • Dr. Eli N. Glezer Ph.D. (Age 53)
    Founder, Chief Scientific Officer & Chair of Scientific Advisory Board
  • Mr. Dalen Meeter (Age 44)
    Sr. VP of Fin. & CFO
  • Mr. Jorge Velarde Jr. (Age 55)
    MBA, Sr. VP of Corp. Devel. & Strategy
  • Mr. Jeff Bullard
    Head of Sales
  • Mr. Vincent Brancaccio (Age 39)
    Sr. VP of HR













OMIC Stock - Frequently Asked Questions

Should I buy or sell Singular Genomics Systems stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Singular Genomics Systems in the last year. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" OMIC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OMIC, but not buy additional shares or sell existing shares.
View OMIC analyst ratings
or view top-rated stocks.

What is Singular Genomics Systems' stock price forecast for 2023?

3 Wall Street research analysts have issued 1-year price targets for Singular Genomics Systems' shares. Their OMIC share price forecasts range from $3.00 to $4.50. On average, they expect the company's stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 92.3% from the stock's current price.
View analysts price targets for OMIC
or view top-rated stocks among Wall Street analysts.

How have OMIC shares performed in 2022?

Singular Genomics Systems' stock was trading at $11.56 on January 1st, 2022. Since then, OMIC stock has decreased by 84.3% and is now trading at $1.82.
View the best growth stocks for 2022 here
.

When is Singular Genomics Systems' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 1st 2023.
View our OMIC earnings forecast
.

How were Singular Genomics Systems' earnings last quarter?

Singular Genomics Systems, Inc. (NASDAQ:OMIC) announced its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by $0.01.

When did Singular Genomics Systems IPO?

(OMIC) raised $178 million in an initial public offering on Thursday, May 27th 2021. The company issued 8,500,000 shares at $20.00-$22.00 per share. J.P. Morgan, Goldman Sachs, BofA Securities, Cowen and UBS Investment Bank served as the underwriters for the IPO.

What is Singular Genomics Systems' stock symbol?

Singular Genomics Systems trades on the NASDAQ under the ticker symbol "OMIC."

Who are Singular Genomics Systems' major shareholders?

Singular Genomics Systems' stock is owned by a variety of institutional and retail investors. Top institutional investors include UBS Group AG (6.57%), BlackRock Inc. (5.25%), Vanguard Group Inc. (2.63%), Platinum Investment Management Ltd. (1.23%), State Street Corp (1.14%) and Keybank National Association OH (0.50%). Insiders that own company stock include James E Flynn, Michael J Pellini and Sheryl L Conley.
View institutional ownership trends
.

How do I buy shares of Singular Genomics Systems?

Shares of OMIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Singular Genomics Systems' stock price today?

One share of OMIC stock can currently be purchased for approximately $1.82.

How much money does Singular Genomics Systems make?

Singular Genomics Systems (NASDAQ:OMIC) has a market capitalization of $129.95 million. The company earns $-98,770,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis.

How many employees does Singular Genomics Systems have?

The company employs 221 workers across the globe.

How can I contact Singular Genomics Systems?

Singular Genomics Systems' mailing address is 10931 N. TORREY PINES ROAD SUITE 100, LA JOLLA CA, 92037. The official website for the company is singulargenomics.com. The company can be reached via phone at 858-333-7830.

This page (NASDAQ:OMIC) was last updated on 12/8/2022 by MarketBeat.com Staff